Currently, there are 103.67M common shares owned by the public and among those 93.24M shares have been available to trade.
The company’s stock has a 5-day price change of 17.02% and 24.14% over the past three months. HUMA shares are trading 115.49% year to date (YTD), with the 12-month market performance up to 112.50% higher. It has a 12-month low price of $1.96 and touched a high of $9.97 over the same period. HUMA has an average intraday trading volume of 3.24 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 7.69%, -10.46%, and 25.43% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Humacyte Inc (NASDAQ: HUMA) shares accounts for 25.93% of the company’s 103.67M shares outstanding.
It has a market capitalization of $730.42M and a beta (3y monthly) value of 1.46. The earnings-per-share (ttm) stands at -$1.26. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.63% over the week and 7.74% over the month.
Earnings per share for the fiscal year are expected to decrease by -12.91%, and 29.10% over the next financial year.
Looking at the support for the HUMA, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on December 11, 2023, with the firm’s price target at $6. Piper Sandler coverage for the Humacyte Inc (HUMA) stock in a research note released on August 14, 2023 offered a Neutral rating with a price target of $3.50. Cantor Fitzgerald was of a view on June 22, 2023 that the stock is Overweight, while Piper Sandler gave the stock Underweight rating on May 16, 2022, issuing a price target of $10- $4. Cowen on their part issued Outperform rating on October 29, 2021.
